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Abstract
Targeting of the drugs administered systemically relies on the higher affinity of ligands for specific
receptors to obtain selectivity in drug response. However, achieving the same goal inside the bladder
is much easier with an intelligent pharmaceutical approach that restricts drug effects by exploiting
the pelvic anatomical architecture of the human body. This regional therapy involves placement of
drugs directly into the bladder through a urethral catheter. It is obvious that drug administration by
this route holds advantage in chemotherapy of superficial bladder cancer and it has now become the
most widely used treatment modality for this ailment. In recent years, the intravesical route has also
been exploited either as an adjunct to an oral regimen or as a second-line treatment for neurogenic
bladder 1, 2. Instillation of DNA via this route using different vectors has been able to restrict the
transgene expression in organs other than bladder. The present review article will discuss the
shortcomings of the current options available for intravesical drug delivery (IDD) and lay a
perspective for future developments in this field.
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Introduction
Systemically administered therapy for the bladder diseases often fails because only a small
fraction of administered drugs reaches the desired site either due to poor absorption or due to
losses from metabolism. IDD can avoid losses from first pass metabolism and allows the
therapeutic effect of a drug to be localized at the desirable site with minimal systemic side
effects. These characteristics can ensure potential and real benefits for patients having morbid
adverse effects from oral administration 3. The pharmaceutical and biotechnology industries
are continuously developing peptide, protein, biopolymer and macromolecular drugs for the
treatment of diseases such as cancer. However, many of these new drugs have poor
bioavailability when administered orally and often fail to induce a clinical response.
Fortunately, IDD can overcome intrinsic shortcomings of oral therapy such as drug or
formulation specific vagaries in absorption, metabolism and renal excretion. For instance, the
metabolite of orally administered Oxybutynin, N-desethyl-oxybutynin (DEO) is known to
cause side effects in some patients 3. Interestingly, intravesical administration of Oxybutynin
avoids its first pass effect and the amount of DEO in serum is drastically reduced. Similarly,
patients with interstitial cystitis (IC) had to wait for 6 months to accrue any benefit from thrice
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daily oral administration of cytoprotective drug misoprostol 4. The need of a prolonged regimen
for achieving efficacy can be traced to low amounts of drug excreted in the urine following
oral administration. It is highly probable that IDD of a cytoprotective drug in cystitis patients
would be able to reduce the duration of treatment. Besides, IDD will also be helpful in cases
where resistant drug target in bladder forces the need of higher drug levels inside the bladder.
However, IDD has to overcome its own set of challenges and most prominent among them is
the low residence time of a drug in the bladder that necessitates frequent instillation.
Conventional vehicles used for the intravesical delivery fail to provide a sustained exposure
of drug inside the bladder, which rarely lasts beyond the first voiding of urine after instillation.
An important obstacle in the success of IDD arises from the low permeability of transitional
epithelium of the bladder also known as urothelium. In the normal condition, the 6-7 cellular
layer thick urothelium maintains high electrochemical gradients between urine and blood. In
the healthy state it is almost impermeable to all the irritants present in urine. However, this
tough barrier against IDD is somewhat compromised in the disease condition and even then
passive diffusion is the only mode of membrane transport possible across urothelium.
Subsequent to drug instillation into the bladder, the concentration of drug in the bladder tissue
was linearly dependent on the concentration of drug in urine 5. Since passive diffusion is the
sole driving force available for intravesical drug absorption, it is logical to expect an increase
in trans-vesical (across the urothelium) drug transport coincident with improvement in the
concentration gradient.
Conversely, trans-vesical transport can be adversely affected by dilution of instilled drug
solution by residual urine in the bladder. Further decrements in the concentration gradient are
also possible from steady accumulation of urine during the duration of instillation. This
influence of the kidney on IDD can be mitigated by reducing the rate of urine production, which
can be achieved with complete bladder emptying prior to dose administration and restricted
fluid intake before and after instillation 6. This clever strategy was able to increase the urinary
drug concentration and improve efficacy without a significant increase in toxicity 6. A phase
III trial on IDD followed these techniques to enhance the penetration of mitomycin C across
urothelium and nearly doubled the recurrence-free rate in superficial bladder cancer patients
7.
1.1. Bladder Permeability Barrier
The water tight barrier between blood and urine formed by urothelium represents the toughest
barrier to drug delivery known to man. The bladder permeability barrier (BPB) for IDD appears
complementary to the impermeable endothelial interface separating blood from brain
interstices known as the blood brain barrier (BBB) for drug delivery into brain. But, BPB may
turn out to be tougher than the BBB because the former is made up of epithelial cells and the
latter by a unique phenotype of endothelial cells lining the blood vessels of the brain. The main
site of BPB is located at the superficial cells in transitional epithelium of bladder called
umbrella cells named because of their characteristic shape (Fig.1) 8, 9. The umbrella cells erect
a water tight barrier with the help of multiple rigid-looking plaques of its asymmetric unit
membrane (AUM) in consort with tight junctions joining its apical surface 10. Nearly 90% of
the apical surface of umbrella cells is covered by rigid plaques that are composed of four major
uroplakins, UPIa (27 kDa), UPIb (28 kDa), UPII (15 kDa), and UPIII (47 kDa) 11. These
uroplakins add to the strength of umbrella cells and to the BPB through the tight assembly of
16-nm particles into hexagonally packed 2D crystals (urothelial plaques). The crystalline lattice
structure of uroplakin interact with specialized lipids of the apical membrane of umbrella cells
to aid in the BPB.
The permeability of urothelium is further augmented by the mucin layer composed of
glycosaminoglycans (GAG) present on the surface of umbrella cells. The hydrophilic nature
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of the GAG layer allows it to form a thin sheet of stationary aqueous layer on umbrella cells.
The GAG layer acts as a major permeability barrier by physically blocking the instilled drug
molecules from reaching the underlying tight junctions and cell membranes. Moreover, the
apical membrane of umbrella cells (AUM) beneath the GAG layer further reinforces the BPB
by its exceptionally low permeability 12-15. The antiadherence property of the GAG layer can
block adhesion of foreign particles including an adenovirus, instilled as vectors of gene
delivery. Parsons and coworkers hypothesized that symptoms of IC are related to changes in
urothelial permeability arising from defects in the GAG layer 16, 17. Nevertheless, the
impermeability of urothelium is frequently exploited for instilling potentially toxic agents into
the bladder for achieving localized pharmacological effect.
2. Therapeutic Considerations for Instilling Potentially Toxic Agents for IC or
Bladder Cancer
The drastic reduction in the incidence of systemic side effects by intravesical route allows the
use of very toxic agents such as dimethylsulphoxide (DMSO) in the treatment of interstitial
cystitis (IC) also known as painful bladder syndrome 18. The first report of IC treatment with
intravesical instillation of DMSO came in 1967 19 and in 1978 it was FDA approved as a 50%
solution (Rimso-50) with a primary indication of IC treatment 20. Another toxic agent
frequently instilled into the bladder is a strain of Mycobacterium tuberculosis, Bacillus
Calmette-Guerin (BCG). Instillation of BCG has now become an established therapy for
recurrent superficial (papillary) bladder carcinoma and carcinoma in situ 21. BCG delays tumor
progression and decreases the need for subsequent cystectomy with improved overall survival
rates 22.
The mechanism of action for BCG is still unclear, although a greater rate of cell turnover has
been postulated. BCG triggers a variety of local immune responses that appear to correlate
with antitumor activity 23, 24. Immunomodulatory activity of BCG prompted its evaluation
for immunotherapy of IC and it showed a favorable outcome in refractory IC patients 25. BCG
instillation is now considered an alternative option for symptomatic treatment of IC 26.
Inflammation is a major component of IC and agents or delivery systems that can modulate
immune response may prove a viable option as an intravesical treatment option for IC
treatment.
Newer forms of IC treatment aim to attack whatever is known for the pathogenesis of IC. The
most consistent finding in most IC patients involves the dysfunction in extracellular matrix
called the GAG layer and localization of a high number of activated mast cells in the bladder
27, 28. The glycosaminoglycans present on the bladder surface include chondroitin 4 and 6
sulfate, dermatan sulfate, heparan sulfate, and hyaluronic acid 29, 30. Treatment of IC by
instilling sodium hyaluronate has been reported in IC patients for possible replenishment of
defective GAG layer 31, 32. Heparin is another GAG effective as a treatment in approximately
50% of IC patients following its instillation 33.
Intravesical treatment of particularly severe chronic IC requires addressing the significant
upregulation of afferents in the bladder 34. C-fiber afferents involved in aberrant micturition
reflex of IC are believed to be silent under normal conditions, but are activated after bladder
irritation and spinal cord injury 35, 36. Down-regulation of sensory nerves by using neurotoxins
like capsaicin, resiniferatoxin RTX or botulinum toxin has proven itself a viable approach in
urology 37, 38. The potent action of capsaicin is restricted only to the afferent fibers in the
bladder wall and possible systemic neurotoxicity is also avoided with IDD 39. The hydrophobic
nature of vanilloids necessitates the use of ethanol as a co-solvent with saline for the instillation
into the bladder. Ethanol solution is well known to induce inflammation after topical
application on tissues 40, 41 and a recent study demonstrated the superiority of nonalcoholic
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solvents for capsaicin when compared against RTX delivered in alcohol 42. Many other options
have been tried to improve aqueous solubility of drugs administered systemically such as
micelles and liposomes.
3. Liposomes & Nanotechnology
Liposomes are spherical vesicles consisting of an aqueous core enclosed in one or more
phospholipid layers, that can be loaded with a great variety of molecules, such as small drug
molecules, proteins, nucleotides and even plasmids 43-47, 48. Liposomes were first studied in
1961 by Bangham 49 and the flexibility in their compositions makes them versatile drug
delivery vehicles (Fig.1). Liposomes are better suited than micelles for use as carriers of water
insoluble drugs administered into the bladder, because instillation of micelles can have
deleterious effects on urothelium 50, 51. Micelles formed by polyamide detergents such as Big
CHAP (N,N-bis-(3-D-Gluconamidopropyl) cholamide) can remove lipids from the apical
membranes of cells lining the bladder and make the urothelium more permeable for drug or
gene transfer 52.
When used for intravenous route, liposomes were able to demonstrate improvement in aqueous
solubility of hydrophobic drugs such as taxol and amphotericin 53. A recent study reported
from our lab used liposomes as a vehicle for capsaicin and evaluated their potential as a vehicle
for intravesical delivery in rats 54. Liposomes were able to deliver capsaicin with efficacy
similar to ethanolic saline, but toxicity to the bladder was drastically reduced. A similar
approach can prove useful in instillation of other vanilloids such as RTX and water insoluble
drugs.
Instillation of liposome encapsulated radiolabeled IFN-α or radiolabeled liposomes into mouse
bladder was able to achieve localized therapy with negligible penetration to other organs 55.
Use of multilamellar liposomes was favored in cell culture studies and use of liposomes as a
delivery vehicle improved the antiproliferative capacity of IFN-α in a resistant bladder cancer
cell line 56. The in vivo effectiveness of liposomes in an orthotopic resistant bladder cancer
model need to be examined in future studies to support the encouraging results obtained on
cell lines.
Liposomes devoid of any drug were successful in promoting wound healing on skin perhaps
by forming a film on the tissue surface 43, 44. Recent studies on non viral gene therapy of skin
wounds confirmed the wound healing properties of liposomes 57, 58. Based on such
encouraging reports, it was logical to expect that instillation of liposomes may be able to palliate
IC symptoms in a rat model of bladder injury, because of the wound healing properties of
liposomes 16, 17. Effect of liposomes alone in absence of any drug was studied in a rat model
of bladder hyperactivity induced by breaching the GAG layer with protamine and thereafter
irritating the bladder with KCl. Liposomes were able to partially reverse the high micturition
frequency induced by protamine sulfate/KCl 59. These observations suggest that liposomes
might enhance the barrier properties of a dysfunctional urothelium and increase its resistance
against irritant penetration.
The apical surface of umbrella cells in urothelium facing urine posses a unique asymmetric
unit membrane (AUM), whose protein component (uroplakins) have been well studied but
information on its lipid component is largely missing 11, 60. The beneficial effect of liposomes
on injured urothelium encourages investigation into lipid composition of urothelium and role
of lipid signaling in normal and hyperactive bladder. Interestingly, all isoforms of a nuclear
receptor family peroxisome proliferator-activated receptor (PPAR) implicated in the control
of inflammatory responses have been localized in transistional epithelium of bladder and
kidney. The functions of these isoforms in kidney have been well reported, where PPAR-α
plays a major role in triggering fatty acid utilization, PPAR-β/δ contributes to survival of renal
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interstitial cell in medullary hyperosmality and PPAR-γ is involved in regulation of renal
hemodynamic and water and sodium transport 61. Though, the functional role of PPAR
isoforms in urothelium remains to be investigated. The link between the family of PPARs and
lipid homeostasis in other tissues may suggest important implications for their role in
permeability of urothelium in health and diseases such as IC.
A promising alternative to liposomes as drug carriers is slowly rising on the horizon from the
field of nanoparticle delivery. Nanotechnology involves the creation and manipulation of
colloidal particles that range from 10 to 1000 nm in size. Nanoparticles are produced by creating
molecular nanostructures by either dissolving, adsorbing, entrapping, encapsulating drug
molecules or by forming drug-polymer complexes. Nanoparticles with a well-defined particle
size and shape can have immense potential for intravesical delivery as they can enhance the
ability of drugs to cross the urothelium. Moreover, higher surface to volume ratio of
nanoparticles can also be responsible for increase in transvesical absorption of encapsulated
drugs. Lu et al designed a rapid releasing gelatin nanoparticles loaded with paclitaxel whose
particle size ranged from 600 to 1,000 nm 62. The paclitaxel nanoparticles showed significant
activity against human bladder cancer cell and resulted in higher tissue concentrations
compared with paclitaxel formulated in the commercial cremophor emulsion 62.
Nanotechnology holds tremendous promise for the future of intravesical delivery of drugs and
genes into the bladder.
4. Gene Therapy of Bladder Cancer
Gene therapy can bring a radical change in the treatment of bladder cancer and other diseases
affecting bladder. Intravesical administration of recombinant interferon (IFN) demonstrated
only limited efficacy against superficial bladder cancer because of the inherent drawback of
the intravesical route 63. Instillation of protein was only able to offer short term treatment of
IFN because of the excretion of the instilled IFN with only a fraction of administered dose
remaining after voiding. It was reasonable therefore to expect that delivery of IFN-α gene into
the urothelium might improve this therapeutic modality and potentially provide a continuous
secretion of IFN into the tumor microenvironment. Indeed, successful transgene expression
into urothelium was able to sustain the production and secretion of the mature 165 amino acid
human IFN-α2b protein inside the bladder 64. Moreover, in vivo gene transfer is a feasible
approach against superficial bladder cancer because of its specific features such as easy external
access for treatment through the urethra and lower risk of gene transfer to other organs 65.
Recent developments such as generation of human superficial bladder tumor cells stably
expressing green fluorescent protein after implantation in the mouse bladder have made it easier
to evaluate efficacy of intravesical therapies and visualize the associated changes in cancer
growth 66.
Harnessing the potential of sequence-specific recognition between complementary nucleic acid
sequences (Watson-Crick base pairing) can also allow control of aberrant gene expression in
the bladder. Overexpression of NGF mRNA in bladder is considered responsible for symptoms
of IC and as expected, viral mediated expression of NGF gene in rat urothelium led to bladder
hyperactivity 67. A short single-stranded oligo fragment can hybridize to its complementary
mRNA target sequence and modify RNA processing either through steric blockade or by
activating RNase H. Antisense approaches have been extensively used both for determining
the function of specific mRNA and therapeutic purposes. It remains to be seen if specific
degradation of target mRNA in bladder can also be achieved by using catalytic RNA
(ribozymes) and DNA (DNAzymes) as similar tools have been successful in other tissues68,
69.
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RNA interference (siRNA) is an emerging frontier of gene therapy with immense therapeutic
potential70. A recent study evaluated the potential of small interfering RNAs (siRNAs) in
blocking mRNA for the enzyme Polo-like kinase-1 (PLK-1) involved in proliferation after
intravesical administration71. PLK controls mitotic entry of proliferating cells and regulate
many aspects of mitosis required for cytokinesis. Future studies for modulating gene expression
may also employ the decoy approach for evaluating the potential of synthetic DNA fragments
in competition against transcription factors. However, the latent potential of rational gene-
based drug design remains unrealized for intravesical delivery largely due to lack of an adequate
drug delivery system. A search is ongoing for suitable vectors for plasmid and oligos that can
be used for intravesical delivery.
4.1. Viral Vectors
The adenovirus genome has been well-characterized and they have been successful in
transducing exogenous DNA to both dividing and non-dividing cell types. Intravesical
administration of replication-incompetent adenovirus was successful in restricting the
transgene expression only to the bladder for two days after administration with several fold
reduced expression by the 3rd day72. The luciferase gene expression was driven by the
cytomegalovirus immediate early promoter in the expression cassette in place of the E1 region
of the adenovirus vector.
Besides, adenoviral mediated delivery of the IFNα2b gene allowed detection of multiple-fold
higher interferon concentration in bladder tissue and urine than those observed with instillation
of the recombinant IFN protein itself 64. The concentration of IFN in urine followed the pattern
of adenoviral mediated luciferase expression in tissue 72 with peak around 2 days and return
to baseline by the 7th day. The gene transfer efficiency using viral vectors is known to be
influenced by various physical parameters such as intravesical volume, instillation pressure
and chemical treatment of urothelium prior to instillation 73. Instillation of higher volumes of
viral vector was able to restrict significantly higher gene expression only to the bladder, but
instillation at higher pressures resulted in higher transgene expression in other systemic organs.
Recent studies employing the orthotopic murine bladder cancer model have demonstrated that
gene transfer efficiency using attenuated vaccinia virus or canarypox virus is better than with
adenovirus 74, 75.
The antiadherence property of the GAG layer present on the surface of urothelium acts as a
nonspecific barrier in transduction of urothelium by adenovirus. Instillation of 22% ethanol in
rodent bladder before administration of adenovirus was able to improve gene transfer because
of disruption in the GAG layer 76. An even greater increase in gene transfer and expression
was achieved by prior instillation of gene transfer-enhancing agent Syn3 64, 77. This
polyamide compound was required to be instilled for an hour at 1 mg/ml concentration on two
consecutive days prior to administration of adenovirus 77. However, a recent study reported
by Connor et al 2005 showed that co-administration of Syn3 with adenovirus is also successful
and infact Syn3 can be used as a vehicle for the adenovirus 64,66. Previously, a similar strategy
of co administering adenovirus with a transduction-enhancing non-ionic polyamide detergent
Big CHAP was used to improve the expression of p53 gene in a phase I study 52. Although,
the use of Syn3 appears to be non-toxic to the bladder tissue, but the use of other transduction
enhancing agents have been shown to produce adverse effects on the urothelium 50, 51,66.
A phase I gene therapy clinical trial based on IFN-α gene is proposed in superficial bladder
cancer patients by using a study design already evaluated in a preclinical study 78. Single
instillation of adenovirus containing IFN-α at doses of 1010-1011 particles/ml along with Syn3
was highly effective in reducing the size of human bladder tumors implanted orthotopically in
nude mice 78. Urine levels of expressed IFN after treatment correlated with efficacy against
bladder cancer model implanted in immunodeficient mice. Although the adenovirus vector
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appeared promising in preclinical study, its potential inflammatory toxicity could not be fully
evaluated in an immunodeficient mouse model.
The dose-limiting toxicity of adenovirus vector containing p53 gene was evaluated in a phase
I study on patients of locally advanced bladder cancer ineligible for cystectomy 79. The vectors
showed no selective tropism for tumoral cells and the expression of specific transgene was
transient as detected in bladder biopsy samples using Reverse-transcriptase polymerase chain
reaction. Immunohistochemical analysis of bladder epithelium also did not reveal any changes
in the protein levels of p53, p21waf1/cip1, or bax 79. Higher efficiency of virus mediated gene
transfer will continue to hold interest for translating the success on murine models to clinical
setup. However, the clinical toxicity of viral vectors observed following systemic
administration will drive the search of nonviral vectors with higher efficiency of gene
transfection. Development of efficient nonviral vectors will also serve the needs of intravesical
delivery.
4.2. Nonviral Vectors
The potential of toxicity from inadvertent systemic absorption of viral vectors from the bladder
has whetted interest in non-viral vectors. Among various approaches tried so far such as gene
gun and electroporation, only the approach of lipoplexes has attracted considerable interest.
Cationic liposomes have facilitated the delivery of DNA into mammalian cells through
endocytosis of the complex followed by its escape into the cytosol from an endocytotic
compartment 80, 81. Interestingly, endocytosis is also a critical process for the time-dependent
changes in the area of bladder surface during voiding and urine storage 11, 82. Thus, it is
possible that the entry of DNA/lipid complex into the urothelium cells is possibly mediated by
endocytosis, which may be further tested using endocytosis inhibitors.
Compared to BCG therapy, IL-2 gene therapy using cytofectins, Dimyristoyl Rosenthal
Inhibitor Ether DMRIE and dioleoylphosphatidylethanolamine DOPE proved better in
improving survival rate of mice bearing orthotopic bladder cancer and inducing long-lasting
tumor-specific immunologic memory 83. In a recent study, Esuvaranathan lab used a different
vector based on cationic liposome, N-[1-(2,3-dioleoyloxyl)propyl]-N,N,N-
trimethylammoniummethyl sulfate and methyl-beta-cyclodextrin-solubilized cholesterol to
transfer plasmid containing IFN-α and GM-CSF into tumors implanted into mouse bladder
84. Cationic liposomes have also been used as a delivery vector for double-stranded siRNA
into the bladder. The in vivo effectiveness of siRNA delivered using liposomes composed of
lipid analogue 2-O-(2-DEAE)-carbamoyl-1,3-O-dioleoylglycerol and egg
phosphatidylcholine was demonstrated in a murine orthotopic bladder cancer model 47.
The authors ruled out the contribution of innate immunity in the efficacy of siRNA against
cancer by the failure of siRNA to induce transcription of IFN-ß gene in murine monocyte cell
line RAW264.7. Therapy based on siRNA is relatively new and its comparative efficacy with
respect to gene therapy in inhibiting bladder cancer needs to be determined in mouse models
to make definitive conclusions about its effectiveness. Nonviral vectors has not been evaluated
for gene transfer in the clinic and a comparative preclinical study on viral and non viral vectors
for gene therapy of bladder cancer will be needed to justify their claim
5. Strategies for Improved Intravesical Therapy
The response of intravesical therapy in bladder cancer and cystitis is often incomplete and
variable among patients from conventional formulations typically maintained in the bladder
for only a short duration (i.e., 2 hours). Incomplete and variable response often seen with the
use of conventional formulations for intravesical therapy can be partly attributed to resistant
drug target or unsuccessful drug delivery to the diseased bladder tissue.
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5.1. Improving the Permeability
Therapy by intravesical route can be further improved by helping drugs cross the permeability
barrier of urothelium by physical (such as iontophoresis) and chemical (such as DMSO)
enhancement methods.
5.1.1. Physical Approaches—The use of electromotive drug administration (EMDA) or
iontophoresis for the enhancement of transdermal drug transport has a long tradition in
medicine 85, 86. Using a very small electric current, iontophoresis increases the permeation
of charged and neutral compounds through the process of electromigration and electro-
osmosis. It is an active and potentially effective method for transporting drugs (such as
mitomycin C, oxybutynin, and bethanechol) through the urothelium into deeper layers of the
bladder 90. Response rate in high risk superficial bladder cancer was improved with increased
bladder uptake of mitomycin C following intravesical electromotive administration 87, 88. In
addition, several clinical reports demonstrate that intravesical EMDA of local anesthetics
results in sufficient anesthesia for transurethral resection of bladder tumors, bladder neck
incision and hydrodistension of the bladder 89-92. A different approach of local microwave-
induced hyperthermia was used by Colombo, 2001 93 to enhance the efficacy of mitomycin
C on small superficial tumor with minimal local side effect after intravesical administration.
In order to further increase transvesical drug permeation with minimal local side effect it would
be interesting to see experiments conducted using a combination of iontophoresis with
chemical enhancers. Electroporation uses higher voltage than that used for iontophoresis to
increase the permeability of tissue under the influence of an electric field. It has been used for
improving intravesical delivery of drugs in bladder carcinoma treatment 94. Voltage used in
electroporation can be reduced to minimize tissue damage by combining electric current with
low intensity ultra sound using the technique called sonophoresis95.
5.1.2. Chemical Approaches—Recently, certain peptides called “cell penetrating
peptides” (CPP) or “protein transduction domains” (PTD) have been shown to be internalized
in most cell types and, more importantly, allow the cellular delivery of conjugated biomolecules
96. They have been successful in crossing the blood brain barrier, but these peptides lack the
ability to be cell selective and are therefore a poor choice for systemic drug targeting 97.
However, instillation into bladder can overcome the poor selectivity of CPPs. Development of
nucleic acid-based drugs is hindered by poor uptake into cells and their conjugation with CPPs
could become an effective strategy for intravesical antisense therapeutics.
We examined the effect of using short length Trans-Activator of Transcription (TAT) peptide
derived from human immunodeficiency virus for intravesical administration of large
macromolecular drugs such as peptide nucleic acid (PNA). Other agents such as cationic lipids
or polymers are ineffective in aiding translocation of PNA and its unassisted cellular uptake is
very poor. PNA have been used for their antisense effect in various studies, because they form
stable duplexes with the target mRNA and arrest translation of proteins 98. PNA has superior
binding properties, and higher stability in biological media such as urine over a wide pH range,
compared to traditional oligonucleotides and ribozymes 99. Eleven amino acid long TAT
peptide was coupled to 18mer antisense PNA by Fmoc chemistry and similar chemistry was
used to tag a fluorescent rhodamine probe. Translocation across rat urothelium was visualized
by confocal microscopy of the red fluorescence of rhodamine in bladder sections (Tyagi et. al.
unpublished observation). Using phage display technology, a peptide motif Ile/Leu-Ser-Gly-
Leu that is selectively internalized in cultured urothelial cells was recently identified 100. It
remains to be seen if conjugation of gene based drugs to this peptide motif can improve their
permeability across the urothelium.
Tyagi et al. Page 8













Currently, treatment of severe overactive bladder requires cystoscopic guided injections of
botulinum toxin A (BOTOX) at 20 to 30 different sites of detrusor in bladder. Botox provides
long lasting effect by blocking the release of acetylcholine from nerve endings to impair
involuntary detrusor contractions 101. IDD of this high molecular weight protein toxin will
require improvement in the permeability for its absorption. The absorption of this dangerous
toxin botox has to be localized as any systemic absorption can prove fatal and therefore
development of delivery techniques in the future has to take that into consideration.
Pretreatment of urothelium with protamine sulfate was tried in rats to improve the permeability
for botox 102, 103. The cationic nature of protamine sulfate allows a charge interaction with
the anionically charged GAG layer leading to slight increases in permeability of urothelium
104, 105.
An exciting new approach for increasing permeability of instilled drugs across BPB may be
the reversible opening of umbrella cell’s tight junctions. Encouraging results were obtained by
increasing paracellular transport (through tight junctions) for intranasal delivery of peptides
and proteins 106. Topical application of chitosan and cyclodextrins is thought to disrupt
intercellular tight junctions and increase paracellular transport 107, 108. Recently developed
quaternized chitosan derivatives such as triethyl chitosan and N-diethyl methyl chitosan might
prove an efficient tool for improving paracellular transport of hydrophilic drugs in the bladder.
These new positively charged chitosan derivatives could also interact with the tight junctions
of colon epithelia 109.
Prior instillation of DMSO has also been reported to enhance the absorption of
chemotherapeutic drug including paclitaxel and pirarubicin 110, 111. Sasaki reported that
intravesical instillation of saponin before administration of anticancer drug (4′-O-
tetrahydropyranyldoxorubicin, THP) can cause vacuolization and swelling of superficial cells,
and the concentration of THP in bladder tissue was significantly higher than that of untreated
animals, but no difference was revealed in plasma concentration 112, 113.
5.2. Increasing Residence Time in the Bladder
Sustained intravesical delivery of drugs can ensure continuous presence of drug in the bladder
without the need for intermittent catheterization and drug concentration in the bladder would
be constant without any peaks and valleys. It is also plausible to expect an increase in efficacy
with increased duration of direct contact between the drug and the abnormal urothelium 55. A
simple and sensible approach for sustained intravesical delivery is prolonged infusion into the
bladder. This technique has often been applied for achieving slow and sustained release of
drugs such as RTX and prostaglandins inside the bladder 114,115. RTX was infused at the
flow rate of 25μl per hour for 10 days using a pigtail catheter inserted into the bladder through
abdomen whereas PGE2 was infused transurethrally into the bladder for 3h in a 4 year old
patient 115.
Forming a drug depot inside the bladder appears to be an attractive option over prolonged
infusion. Aqueous solutions of poly (ethylene glycol-b-[DL-lactic acid-co-glycolic acid]-b-
ethylene glycol) (PEG-PLGA-PEG) triblock copolymers form a free-flowing solution at room
temperature and become a viscous gel at body temperature of 37°C 116. Its formulation does
not require organic solvent and products from bioerosion of the biocompatible polymer are
non-toxic PEG, glycolic acid and lactic acid 117. As such, a thermosensitive hydrogel formed
by PEG-PLGA-PEG has been used for in situ gel formation for a depot of hydrophobic and
hydrophilic drugs following subcutaneous administration in rats 118.
The triblock copolymer was used for sustaining the residence time of hydrophobic drugs in rat
bladder after its instillation at room temperature. The temporal kinetics of drug excreted from
hydrogel loaded with fluorescent probes can be studied by measurement of fluorescence in
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urine. Sustained delivery of misoprostol afforded by thermosensitive hydrogel was able to
protect the rat bladder against cyclophosphamide induced cystitis 119. It would be interesting
to discover the effect of loading wound healing agents such as growth factors into hydrogels
instilled into damaged bladder and assess the speed of wound healing in urothelium.
5.2.1. Bioadhesion—Bioadhesion or mucoadhesion defines the interaction between a
biological surface such as bladder mucosa (urothelium) and the polymer. The presence of a
mucinglycocalyx domain in the bladder mucosa tempts its utilization for prolonging the
residence time of drugs through bioadhesion 120. However, long before bioadhesion caught
the fancy of drug delivery scientists; this powerful approach has been exploited by bacteria
Escherichia coli for its adhesion to the bladder mucosa. As a matter of fact, the urinary tract
infections are initiated by adhesion of uropathogenic E. coli to uroplakin receptors of umbrella
cells through the FimH adhesin located at the tips of its type 1 pili 121. An IDD system based
on bacterial adhesion factors could be a smart and efficient mechanism for increasing adhesion
to epithelial surfaces 122.
Application of bioadhesion for IDD should be able to fulfill three main criteria; quick adhesion
to the urothelium after instillation, should not bottleneck voiding of urine and should be retained
in place for at least several hours. Adhesion between mucoadhesive polymers and extracellular
matrix mucin found on the bladder surface is usually based on the attractive and repulsive
forces operating at the molecular level. The efficiency of drug absorption is increased after
coupling bioadhesion characteristics to microspheres, liposomes or nanoparticles because of
improved intimate contact with the mucus layer. Microspheres based on chitosan are strongly
mucoadhesive and their ocular instillation was able to increase the ocular residence time and
decrease the frequency of administration for acyclovir 123.
Mucoadhesive materials are generally hydrophilic polymers that swell significantly in contact
with water and eventually undergo complete dissolution. The molecules of hydrophilic
polymers generally have hydroxyl, carboxyl or amine groups that favor adhesion to the mucosal
surface upon wetting. The bioadhesive strength increases with an increase in molecular weight
of polymer and these polymers can be categorized into following classes: anionic polymers
such as sodium carboxymethyl cellulose and sodium alginate, cationic polymers such as
chitosan and dextrans, nonionic polymers such as polyvinylpyrollidone, and cellulose
derivatives such as hydroxypropylmethyl cellulose.
Post-operative chemotherapy in mice was successful with bioadhesive carriers based on
polymers such as algin, chitosan and fibrinogen loaded with anticancer drugs 124. Bioadhesive
microspheres poly(methylidene malonate-2.1.2) were able to release paclitaxel at the
urothelium/urine interface of the mouse bladder for two days 120 and a gelatin based delivery
system could release drugs for 12 days in the rabbit bladder 125. Another well known polymer
is polyethylene glycol which improves bioadhesion by non-specific interpenetration of its
polymer chains with mucus 126. Polymers such as chitosan and polycarbophil are ideal for a
hydrophilic drug because they were able to retain good adhesion to isolated porcine urinary
bladder after being fully hydrated 127, 128.
Temporal and spatial monitoring of instilled microparticles is possible with the technique of
magnetic resonance imaging (MRI) 129. Polymeric microparticles were encapsulated with
MRI contrast agent gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) for measuring
T1 relaxation rate of particles till 5 days after instillation. Partial clinical success has also been
achieved through the use of mucoadhesion for IDD of oxybutynin in patients who suffer side
effects from its metabolite N-desethyl-oxybutynin 130. Oxybutynin chloride was instilled
twice daily at a dosage of 0.5 mg/ml in a case study involving 6 overactive bladder patients.
The mucoadhesive solution of drug was prepared by adding 5% w/w hydroxypropylcellulose
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(HPC) to the oxybutynin solution to improve intravesical delivery of oxybutynin 130. The
urodynamic studies performed on patients before starting the treatment and at 1 week and 3
years after the first instillation of oxybutynin revealed a significant increase in bladder capacity
in 4 out of 6 patients.
Anchoring of lectins, bacterial adhesins and antibodies, etc. on the surface of the liposomes or
microspheres can improve the therapeutic benefit after IDD of these carriers. Highly
glycosylated proteins present at the bladder surface can specifically and non-covalently bind
with lectins that are proteins of non-immune origin 131, 132. Therefore, attaching lectins to
instilled drugs or delivery system can lend them bioadhesive characteristic for prolonged
residence time 133, 134. Apart from lectin-mediated drug delivery systems, the carbohydrate
specificity of mucus is also utilized by microorganisms to adhere to the gut or bladder mucosa
135.
6. Summary and Future directions
IDD can prove to be a sound alternative when disease has become refractory to treatment by
drugs administered from other routes. If costs of treatment include physician visits, catheters,
lubricant and man-hours required in getting the treatment are included then IDD can proved
to be more expensive than oral drug administration. Besides, insertion of a catheter in the
urethra can be a cause of discomfort in some patients and risk of UTI from IDD is possible if
done carelessly.
In summary, Table 1 shows the current methods of IDD and the practice of IDD using various
physical and chemical agents is also illustrated in Fig.3. Among the IDD approaches for
improving bladder permeability for instilled drugs, the physical approach of iontophoresis has
gained wider acceptance in the clinic than the approach of using DMSO or protamine to
chemically ablate the urothelium. The approach most effective for improving residence time
inside the bladder so far is bioadhesion and its pre-clinical success has been reproduced in
different labs. There is no doubt on the safety of liposomes as a carrier for drug or gene either
systemically or via IDD. However, gene transfer efficiency of lipoplexes fall short of viral
vectors and the higher gene transfer efficiency of adenovirus after co-administration with Syn3
justifies its clinical evaluation to realize the promise of gene therapy in bladder. The preclinical
success of intravesical gene therapy in bladder cancer encourages its evaluation in treatment
of IC. Unlike bladder cancer, the genes responsible for cystitis remain to be identified before
therapy can be initiated. Further improvements in delivery systems would be necessary to
optimize the delivery of gene, siRNA, antisense and proteins.
These macromolecules are very expensive to produce and methods need to be developed to
avoid the loss of instilled drugs in voided urine after administration. The search for an effective
carrier that can ferry across GAG layer with minimum toxicity still continues for
macromolecular based therapy. As illustrated in Fig.1, GAG layer is the primary barrier that
retards the permeability of drugs across the bladder lumen. Agents such as protamine and
transduction enhancing agents compromise the GAG layer for increased drug or gene delivery
by IDD. The delivery systems using bioadhesion will continue to gain interest for extending
the drug exposure in the bladder.
Future improvements in IDD are likely to gain from developments made in the field of
nanotechnology. The techniques of bioluminenescence and fluorescence can be used to allow
temporal and spatial monitoring of instilled drug carriers. It would be interesting to see how
bioadhesive characteristics affect the behavior of liposomes and nanoparticles after instillation
into the bladder. Moreover, since IDD is drug delivery across a mucosal surface and therefore
future developments in this field can borrow from the developments made in drug delivery
across other mucosal surfaces such as eye, colon, rectum and vagina.
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Illustration of bladder permeability barrier established by uroplakin covered umbrella cells of
bladder epithelium (urothelium) and GAG layer that prevents adhesion.
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Schematic illustration of liposome and sites of drug entrapment.
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Schematic Diagram to Illustrate Advanced Delivery Options for Intravesical Drug & Gene
Delivery.
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Table 1
Use of delivery options in IDD for different drugs or therapeutic entities





Iontophoresis & electroporation Suited for Low Mol.wt. Drugs Mitomycin C Yes Di Stasi, et
al 2003
DMSO & saponins Cytotoxic and Poor Patient
Acceptance
Paclitaxel No Chen et al,
2003
Liposomes Tissue Friendly Gene vector Capsaicin, siRNA, IFNα,
IL-2






Bioadhesive microspheres Increased residence time Paclitaxel, Mitomycin C,
5FU, Oxybutynin
Yes Le Visage et
al, 2004




Thermosensitive hydrogel Higher Drug Loading capacity Capsaicin & Misoprostol No Tyagi et al,
2004
Adenovirus Higher transduction efficiency p53 gene, Yes Pagliaro et
al, 2003
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